New cancer antibodies and ADCs
Several new cancer medicines are approved in China but not yet in Canada, the US or the EU. Examples include ivonescimab, an antibody that blocks both PD-1 and VEGF, cadonilimab, which blocks PD-1 and CTLA-4, and sacituzumab tirumotecan, an antibody–drug conjugate that targets TROP2.
Who it may suit
- Selected lung, cervical, stomach and breast cancers
- Patients whose tumour markers match the approved use
- People whose home options have been used up or are not suitable
What happens
- Your oncologist’s records and biomarker results are reviewed
- Consultation with the oncology team in China
- Treatment is given as an infusion every 2 to 3 weeks
- Planning how treatment continues after you return home
From 2 weeks for the first cycles. Ongoing treatment may need repeat visits.
Some of these medicines may be approved in the West soon. For example, a US decision on ivonescimab is due in November 2026. We check the current status for every case.
Things to know. Side effects include immune reactions, bleeding risk and low blood counts. Bringing medicines home is subject to import rules, so we plan this with you and your doctor.
Why an introduction matters
Many of China’s leading specialists work in busy public hospitals without international patient offices. They rarely answer enquiries from abroad directly, and a file sent without an introduction often goes unread. Cases usually reach them through people they already know and trust. Our team on the ground makes that introduction, presents your case properly in Chinese, and follows up until you have an answer.
Some programmes, especially stem-cell and other cell treatments, are experimental. We introduce them only if you ask and your own specialist agrees, and we never describe them as cures.